Single, dual and triple incretin-receptor research

Semaglutide, Tirzepatide and Retatrutide are not interchangeable labels. Published studies describe different receptor profiles: GLP-1 agonism, combined GIP and GLP-1 agonism, and combined GIP, GLP-1 and glucagon receptor agonism respectively.

Human trials can establish findings for the studied investigational or authorised medicine under a defined protocol. They do not validate an unrelated research product, dosage or route, and this hub does not provide treatment guidance.

For laboratory comparison, record the precise compound, receptor assay, sample amount and analytical report. Apex links measured report results to product families without claiming that all variants are covered.